WASHINGTON, Feb 26 (Reuters) - Drug manufacturer HikmaPharmaceuticals Plc will sell the rights and assets oftwo generic drugs and relinquish its U.S. marketing rights to athird generic drug in order to settle Federal Trade Commissioncharges that Hikma's proposed $2 billion acquisition of Roxanewould likely be anticompetitive, the FTC said on Friday.
The agency said the proposed consent order "preservescompetition by requiring the companies to divest toPennsylvania-based Renaissance Pharma Inc three strengths ofanti-inflammatory and immunosuppressant prednisone tablets andall strengths of lithium carbonate capsules, used to treatbipolar disorder."
Roxane Labs is the U.S.-based generics unit of Germandrugmaker Boehringer Ingelheim. (Reporting by Washington Newsroom; Editing by Jeffrey Benkoe)
Hikma Pharmaceuticals (HIK)
